Open Book Extracts Partners With Nalu Bio To Commercialize Synthetic THCV And Rare Cannabinoids

Open Book Extracts (OBX) entered into a R&D and commercialization partnership with Nalu Bio.

The partnership with OBX will allow Nalu Bio to advance its THCV production method from research and development to commercial-scale manufacturing using their proprietary and scalable synthesis platform. With a 76,000 sf. NSF- and ISO 9001-certified research and production facility near Durham, North Carolina, OBX and Nalu Bio plan to begin initial production of THCV in September 2022 with market-ready compounds available before the end of the year.

Both OBX and Nalu Bio envision a range of additional cannabinoids to be released through this partnership. The products manufactured using Nalu Bio's method will be an addition to the current OBX portfolio, including a broad range of cannabinoids from hemp and natural sources, including CBD, CBN, CBC, CBG, CBT, CBDa, CBGa, CBDV, and THCV.

Matthew Roberts, CTO of Nalu Bio stated, "Our THCV is produced in highly scalable reactors at factory-scale, using low-cost, safe and effective starting materials. Nalu Bio and OBX are both innovators in their respective fields, and this partnership is mutually beneficial for two industry leaders. Nalu Bio prides itself on partnering excellence, and we're excited to deliver high-quality, safe, and low-cost cannabinoid ingredients and products to the market."

Since inception, OBX has taken a holistic approach to the cannabinoid industry, designing a cannabinoid ingredient portfolio to include botanical, synthetic, and biosynthetic cannabinoids. Certain jurisdictions, such as Japan, or certain industry segments, such as cosmetics, may prefer synthetic ingredients based on regulatory guidance. Synthetic ingredients offer the additional benefit of cost efficiency at scale, allowing for the production of bioidentical synthetic cannabinoids at significantly lower cost than agricultural extraction and refinement methods.

Dave Neundorfer, OBX CEO, stated, "I am excited about the value Nalu Bio and OBX will bring to the cannabinoid therapeutics market. This partnership is well-positioned to meet the needs of the growing synthetic cannabinoid market and deliver potentially life-changing products to consumers worldwide."

Photo: Benzinga; Sources: courtesy of geralt, lindsayfox via Pixabay

Related News

This Week's Cannabis Career Moves: Khiron, Flora Growth, Agrify, Hempsmart And More

Can Cannabinoids Work Synergistically In Treatment Of Pain? Here's What One Study Reveals

Open Book Extracts & Biopharmaceutical Research Company Establish Research & Development Collaboration